360° SearchNetwork Hot Spots Trends Time Series

Contrave

Type: Product

Name: Contrave

First reported 5 hours ago - Updated 2 hours ago - 1 reports

Sector Update: Healthcare

Healthcare stocks are narrowly lower, with the NYSE Healthcare Sector Index dropping about 0.2% and shares of healthcare companies in the S&P 500 sliding around 0.1% as a group.In company news, Arena Pharmaceuticals Inc. ( ARNA ), Orexigen Therapeutics ... [Published Nasdaq - 5 hours ago]

Entities: Health Care, Weight Loss, Obesity, Contrave

First reported 7 hours ago - Updated 6 hours ago - 3 reports

Obesity Gets Some Respect (ARNA) (VVUS) (OREX)

Shares of obesity drug makers Arena Pharmaceuticals (NASDAQ: ARNA), VIVUS (NASDAQ: VVUS) and Orexigen (NASDAQ: OREX) are higher Wednesday after the American Medical Association officially recognized obesity as a disease."Recognizing obesity as a disease ... [Published Street Insider - 6 hours ago]

Entities: Obesity, Qsymia, Vivus Inc

First reported Jun 11 2013 - Updated Jun 12 2013 - 1 reports

A Recent History of Legal Weight Loss Drugs

Like finding a cure for hair loss or the secret to female pleasure, one of the holy grails of the pharmaceutical industry is inventing a pill that will help people lose weight without dying. Except for some reason it keeps not working out, because side ... [Published Jezebel - Jun 11 2013]

Entities: Weight Loss, Drugs, Qnexa, Sibutramine

First reported Jun 07 2013 - Updated Jun 08 2013 - 1 reports

FDA Food & Drug Administration

Belviq goes on sale June 11

SAN DIEGO — Arena Pharmaceuticals’ highly anticipated weight-loss drug, Belviq, will go on sale on Tuesday, the San Diego company announced today.Arena’s marketing partner, the Japanese pharmaceutical company Eisai, will actually sell the drug, which ... [Published U-T San Diego - Jun 07 2013]

Entities: Qsymia, Drugs, FDA Food & Drug Administration, Contrave, Orexigen

First reported May 31 2013 - Updated May 31 2013 - 1 reports

UAL Corporation

UAL, OREX, PLG, DM, AWI, MNOV Are Seasonally Ripe To Go Down In the Next Five Weeks

BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of United Continental Holdings Inc (NYSE:UAL), Orexigen Therapeutics Inc (NASDAQ:OREX), PLATINUM GROUP METALS LTD (AMEX:PLG), DOLAN COMPANY (THE) (NYSE:DM), Advent Wireless Inc (NYSE:AWI), ... [Published Individual.com - May 31 2013]

Entities: UAL Corporation, Short Selling, MediciNova Inc, Orexigen Therapeutics Inc

First reported May 30 2013 - Updated May 30 2013 - 1 reports

Orexigen Therapeutics Inc

Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference

About Orexigen$ TherapeuticsOrexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave$, which has completed Phase 3 clinical trials and for which a New Drug Application ... [Published StockHouse USA - May 30 2013]

Entities: Orexigen Therapeutics Inc, Healthcare Conference, Contrave

First reported May 22 2013 - Updated May 23 2013 - 3 reports

Orexigen Therapeutics, Inc. (OREX), And Three Pipeline Obesity Treatments You Should Watch

Obesity is a growing pandemic for many industrialized nations , especially in the U.S., where it now affects almost 36% of adults and 17% of adolescents . As with any sweeping problem, there are many ways to attack obesity. One new approach is through ... [Published InsiderMonkey.com - May 23 2013]

Entities: Orexigen Therapeutics Inc, Obesity, Contrave

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Orexigen Therapeutics Q1 net loss increases

Orexigen Therapeutics, Inc., a biopharmaceutical company, has reported that net loss for the first quarter ended March 31, 2013 was $19.37 million, or $0.21 loss per share, compared to a net loss of $10.41 million, or $0.16 loss per share, for the same ... [Published Individual.com - May 21 2013]

Entities: Orexigen Therapeutics Inc, Contrave, Orexigen, Diabetes

First reported Mar 17 2013 - Updated Mar 17 2013 - 1 reports

These Drug Makers Are Letting Growth Opportunities Slide By

It takes a lot of diligence, a lot of talent, and sometimes even the perfect alignment of the stars for pharmaceutical manufacturers to produce a successful drug. Obstacles can materialize at many points in a drug’s production timeline. Developing, ... [Published Wall St. Cheat Sheet - Mar 17 2013]

Entities: Drugs, Qsymia, Health Care

First reported Mar 14 2013 - Updated Mar 14 2013 - 1 reports

Orexigen Therapeutics' CEO Discusses Q4 2012 Results - Earnings Call Transcript

Orexigen Therapeutics, Inc. ( OREX ) Q4 2012 Earnings Call March 13, 2013, 05:00 pm ET Executives Heather Turner - VP & General Counsel Mike Narachi - President & CEO Mark Booth - Chief Commercial Officer Preston Klassen - SVP, Global Contrave ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Mar 14 2013]

Entities: Orexigen Therapeutics Inc, Marko Kozul, Mark Booth, Charles Duncan

First reported Jan 14 2013 - Updated Jan 14 2013 - 1 reports

Arena Pharmaceuticals, May Be The Last Chance To Get In Under $10

By Rx Stocks : Finally, news that the DEA recommended Schedule 4 classification for Arena's ( ARNA ) Belviq on December 28, 2012. This is a classification similar to widely used insomnia drugs Ambien, Lunesta, and Sonata, although Belviq likely has ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Jan 14 2013]

Entities: Arena Pharmaceuticals Inc, Eszopiclone, Obesity

First reported Jan 07 2013 - Updated Jan 07 2013 - 1 reports

Will Vivus’s Weight-Loss Drug Fall Flat?

The poor sales of Vivus ’s ( NASDAQ:VVUS ) anti-obesity pill Qsymia in the last quarter were somewhat surprising. After all, the company introduced its weight-loss drug in late September, ahead of Arena Pharmaceuticals’ ( NASDAQ:ARNA ) Belviq and ... [Published Wall St. Cheat Sheet - Jan 07 2013]

Entities: Drugs, Qsymia, QVT, Contrave, Orexigen Therapeutics Inc

Quotes

"Recognizing obesity as a disease will help change the way the medical community tackles this complex issue that affects approximately one in three Americans" Dr. Patrice Harris, a member of the associationâs board, said in a statement

Obesity Gets Some Respect (ARNA) (VVUS) (OREX) [Published Street Insider - 6 hours ago]

...Doctors can now say things like, "Joe, you are overweight. The AMA recently classified obesity as a disease and there are steps we can take to mitigate the problems." Instead of the patient having a stigma about their condition they feel vindicated in that years of weight troubles are now accepted as a medical disease...

American Medical Association Decision Can Boost Arena, Vivus, And Orexigen [Published Seeking Alpha - 17 hours ago]

1997 - Sibutramine, or Meridia, is put on the market. In 2010, the FDA pulls Meridia because of a trial study done that "demonstrated a 16 percent increase in the risk of serious heart events" in patients who used sibutramine...

A Recent History of Legal Weight Loss Drugs [Published Jezebel - Jun 11 2013]

...By tracking the size and price of each montha'a "s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin."

UAL, OREX, PLG, DM, AWI, MNOV Are Seasonally Ripe To Go Down In the Next Five Weeks [Published Individual.com - May 31 2013]

More Content

sort by: Date \| Relevance
Arena, Vivus Look Good (And It Has Nothing to D... [Published InvestorPlace.com - 4 hours ago]
Sector Update: Healthcare [Published Nasdaq - 5 hours ago]
Obesity Gets Some Respect (ARNA) (VVUS) (OREX) [Published Street Insider - 6 hours ago]
MannKind Corporation (MNKD), Orexigen Therapeut... [Published InsiderMonkey.com - 7 hours ago]
2 Biotech Approval Outcomes That Might Affect You [Published Motley Fool - 7 hours ago]
American Medical Association Decision Can Boost... [Published Seeking Alpha - 17 hours ago]
A Recent History of Legal Weight Loss Drugs [Published Jezebel - Jun 11 2013]
Weight-loss category expands by one [Published Medical Marketing And Media - Jun 11 2013]
Belviq goes on sale June 11 [Published U-T San Diego - Jun 07 2013]
UAL, OREX, PLG, DM, AWI, MNOV Are Seasonally Ri... [Published Individual.com - May 31 2013]
Orexigen Therapeutics to Present at the Jefferi... [Published StockHouse USA - May 30 2013]
Is Novo A Threat To Arena, Vivus, And Orexigen? [Published BioPortfolio - May 30 2013]
Is Novo A Threat To Arena, Vivus, And Orexigen? [Published Seeking Alpha - May 30 2013]
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc.... [Published InsiderMonkey.com - May 28 2013]
Obesity Data on Novo Nordisk's Victoza Zacks [Published Yahoo! Finance - May 28 2013]
Sirius XM And Arena Pharmaceuticals - More Para... [Published Seeking Alpha - May 28 2013]
Arena - Good Sales, Bad Sales, Long And Short [Published Seeking Alpha - May 24 2013]
Arena Pharmaceuticals, Inc. (ARNA): Why This Ob... [Published InsiderMonkey.com - May 23 2013]
Orexigen Therapeutics, Inc. (OREX), And Three P... [Published InsiderMonkey.com - May 23 2013]
Will Arena's Belviq Be The Next Anti-Obesity Dr... [Published Seeking Alpha - May 23 2013]
3 Pipeline Obesity Treatments You Should Watch [Published Motley Fool Discussion Boards - May 23 2013]
Orexigen Therapeutics' CEO Presents at 2013 UBS... [Published Seeking Alpha - May 22 2013]
Orexigen Therapeutics Q1 net loss increases [Published Individual.com - May 21 2013]
These Drug Makers Are Letting Growth Opportunit... [Published Wall St. Cheat Sheet - Mar 17 2013]
Orexigen Therapeutics' CEO Discusses Q4 2012 Re... [Published Healthcare Sector and Stocks Analysis from Seek ... - Mar 14 2013]
Arena Pharmaceuticals, May Be The Last Chance T... [Published Healthcare Sector and Stocks Analysis from Seek ... - Jan 14 2013]
Will Vivus’s Weight-Loss Drug Fall Flat? [Published Wall St. Cheat Sheet - Jan 07 2013]
Orexigen Therapeutics Announces Progress with F... [Published PR Newswire: Health - Jan 07 2013]

Blogs

sort by: Date \| Relevance
These Drug Makers Are Letting Growth Opportunit... [Published Wall St. Cheat Sheet - Mar 17 2013] It takes a lot of diligence, a lot of talent, and sometimes even the perfect alignment of the stars for pharmaceutical manufacturers to produce a successful drug. Obstacles can materialize at many points in a drug’s production timeline. Developing, ...
Will Vivus’s Weight-Loss Drug Fall Flat? [Published Wall St. Cheat Sheet - Jan 07 2013] The poor sales of Vivus ’s ( NASDAQ:VVUS ) anti-obesity pill Qsymia in the last quarter were somewhat surprising. After all, the company introduced its weight-loss drug in late September, ahead of Arena Pharmaceuticals’ ( NASDAQ:ARNA ) Belviq and ...

Press Releases

sort by: Date \| Relevance
Orexigen Therapeutics Announces Progress with F... [Published PR Newswire: Health - Jan 07 2013]